154 related articles for article (PubMed ID: 33140924)
1. Preterm Birth and 17OHP - Why the FDA Should Not Withdraw Approval.
Greene MF; Klebanoff MA; Harrington D
N Engl J Med; 2020 Dec; 383(24):e130. PubMed ID: 33140924
[No Abstract] [Full Text] [Related]
2. Withdrawing Approval of Makena - A Proposal from the FDA Center for Drug Evaluation and Research.
Chang CY; Nguyen CP; Wesley B; Guo J; Johnson LL; Joffe HV
N Engl J Med; 2020 Dec; 383(24):e131. PubMed ID: 33140923
[No Abstract] [Full Text] [Related]
3. A chronicle of the 17-alpha hydroxyprogesterone caproate story to prevent recurrent preterm birth.
Nelson DB; McIntire DD; Leveno KJ
Am J Obstet Gynecol; 2021 Feb; 224(2):175-186. PubMed ID: 33035472
[TBL] [Abstract][Full Text] [Related]
4. Confirmatory Trial for Drug to Prevent Preterm Birth Finds No Benefit, So Why Is It Still Prescribed?
Rubin R
JAMA; 2020 Apr; 323(13):1229-1232. PubMed ID: 32186660
[No Abstract] [Full Text] [Related]
5. Disparities in 17-Hydroxyprogesterone Caproate Offer and Uptake in Pregnancies at a Risk of Preterm Birth.
Berhie SH; Riley LE; Bryant AS
Am J Perinatol; 2019 Aug; 36(10):1066-1071. PubMed ID: 30508869
[TBL] [Abstract][Full Text] [Related]
6. Racial and ethnic disparities in use of 17-alpha hydroxyprogesterone caproate for prevention of preterm birth.
Yee LM; Liu LY; Sakowicz A; Bolden JR; Miller ES
Am J Obstet Gynecol; 2016 Mar; 214(3):374.e1-6. PubMed ID: 26829989
[TBL] [Abstract][Full Text] [Related]
7. Accelerated Approval of 17α-Hydroxyprogesterone Caproate: A Cautionary Tale.
Godlewski BJ; Sobolik LI; King VJ; Harrod CS
Obstet Gynecol; 2020 May; 135(5):1207-1213. PubMed ID: 32282587
[TBL] [Abstract][Full Text] [Related]
8. FDA Revokes Approval for Preterm Birth Drug Makena.
Harris E
JAMA; 2023 May; 329(17):1444. PubMed ID: 37043247
[No Abstract] [Full Text] [Related]
9. Defining the clinical response to 17-alpha hydroxyprogesterone caproate.
Caritis SN; Hauspurg A; Venkataramanan R; Lemon L
Am J Obstet Gynecol; 2018 Dec; 219(6):623-625. PubMed ID: 30171841
[No Abstract] [Full Text] [Related]
10. Re-examining the Meis Trial for Evidence of False-Positive Results.
Sibai B; Saade GR; Das AF
Obstet Gynecol; 2020 Sep; 136(3):622-627. PubMed ID: 32769653
[TBL] [Abstract][Full Text] [Related]
11. Progestogens in singleton gestations with preterm prelabor rupture of membranes: a systematic review and metaanalysis of randomized controlled trials.
Quist-Nelson J; Parker P; Mokhtari N; Di Sarno R; Saccone G; Berghella V
Am J Obstet Gynecol; 2018 Oct; 219(4):346-355.e2. PubMed ID: 29614278
[TBL] [Abstract][Full Text] [Related]
12. Factors Associated with Utilization of 17-Hydroxyprogesterone Caproate for the Prevention of Recurrent Preterm Birth.
DeNoble AE; Wynn CE; Weaver KE; Wheeler SM; Swamy GK
Am J Perinatol; 2020 Feb; 37(3):264-270. PubMed ID: 30708392
[TBL] [Abstract][Full Text] [Related]
13. FDA approved vs. Pharmacy compounded 17-OHPC-current issues for obstetricians to consider in reducing recurrent preterm birth.
Gandell DL; Randell MD; Gudeman JL
Curr Med Res Opin; 2020 Aug; 36(8):1393-1401. PubMed ID: 32544354
[TBL] [Abstract][Full Text] [Related]
14. Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial.
Price JT; Vwalika B; Freeman BL; Cole SR; Mulenga HB; Winston J; Mbewe FM; Chomba E; Mofenson LM; Rouse DJ; Goldenberg RL; Stringer JSA
BMC Pregnancy Childbirth; 2019 Feb; 19(1):81. PubMed ID: 30813934
[TBL] [Abstract][Full Text] [Related]
15. 17α-Hydroxyprogesterone Caproate and the Risk of Glucose Intolerance in Pregnancy: A Systematic Review and Meta-analysis.
Eke AC; Sheffield J; Graham EM
Obstet Gynecol; 2019 Mar; 133(3):468-475. PubMed ID: 30741815
[TBL] [Abstract][Full Text] [Related]
16. SMFM Statement: Use of 17-alpha hydroxyprogesterone caproate for prevention of recurrent preterm birth.
Society for Maternal-Fetal Medicine (SMFM) Publications Committee. Electronic address: pubs@smfm.org
Am J Obstet Gynecol; 2020 Jul; 223(1):B16-B18. PubMed ID: 32277894
[TBL] [Abstract][Full Text] [Related]
17. Unjustified increase in cost of care resulting from U.S. Food and Drug Administration approval of Makena (17α-hydroxyprogesterone caproate).
Cohen AW; Copel JA; Macones GA; Menard MK; Riley L; Saade GR
Obstet Gynecol; 2011 Jun; 117(6):1408-1412. PubMed ID: 21471853
[TBL] [Abstract][Full Text] [Related]
18. Comparison of oral Dydrogesterone and 17-α hydroxyprogesterone caprate in the prevention of preterm birth.
Alizadeh F; Mahmoudinia M; Mirteimoori M; Pourali L; Niroumand S
BMC Pregnancy Childbirth; 2022 Mar; 22(1):167. PubMed ID: 35232423
[TBL] [Abstract][Full Text] [Related]
19. 17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going?
Manuck TA
Semin Perinatol; 2017 Dec; 41(8):461-467. PubMed ID: 28947068
[TBL] [Abstract][Full Text] [Related]
20. Immune effects of 17α-hydroxyprogesterone caproate.
Al-Lami RA
Am J Obstet Gynecol; 2022 Oct; 227(4):671-675. PubMed ID: 35779586
[No Abstract] [Full Text] [Related]
[Next] [New Search]
